The National Institute for Health and Care Excellence (NICE) has endorsed the use of Gilead Sciences’ Sovaldi, determining it is, in fact, cost effective. However, England’s National Health Service (NHS) is postponing the widespread availability of Sovaldi until the end of July. Despite the NHS’ reasons for delay, patient advocates believe it is really a matter of cost. Read more here. (Source: Jeanne Whalen, The Wall Street Journal, 1/22/15)
You are here: / / What Is The Real Reason Behind Sovaldi’s Delay In England?